Prostate Cancer

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

As fellows in oncology, we are constantly required to assimilate data, interpret diagnostic tests, decide on appropriate treatment regimens, and employ compassionate care in an increasingly truncated allotment of time.

Research from Chile suggests that low levels of free testosterone indicate that an apparently low-risk case of prostate cancer will require treatment.

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index, and prostate cancer risk.

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.

Two recently approved drugs for the treatment of advanced prostate cancer-radium-223 (Xofigo) and abiraterone acetate (Zytiga)-will be studied in combination in a phase III clinical trial.

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Researchers are making progress in identifying biomarkers and developing assays that will help clinicians improve the management of patients with prostate cancer from screening strategies to making therapy choices

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

One of the ongoing debates in US politics involves the pros and cons of big government versus small government: Does big automatically equal bureaucracy and groupthink while small inherently fosters individual creativity and enterprise?

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

As with other new therapies that have been approved in recent years for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), researchers are not entirely certain about how best to fit radium Ra 223 dichloride (Xofigo) into the emerging paradigm

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.